New cocktail therapy aims to shrink tough lung cancers
NCT ID NCT07538271
First seen Apr 21, 2026 · Last updated May 08, 2026 · Updated 3 times
Summary
This study tests a new treatment plan for people with extensive-stage small cell lung cancer (ES-SCLC) who have not had prior therapy. Participants receive a combination of benmelstobart (an immunotherapy), anlotinib (a targeted drug), and chemotherapy, followed by chest radiation. The goal is to see if this approach shrinks tumors and delays progression. About 33 adults aged 18-75 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.